Drugs / Farletuzumab Ecteribulin
Farletuzumab Ecteribulin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03386942 | Nov 2017 → Oct 2022 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04300556 | Aug 2020 → Aug 2030 expected | cancer | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05613088 | Feb 2023 → Jun 2024 | ovarian neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT05577715 | Nov 2022 → Aug 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-06-06 | Eisai Inc. | Results EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513) Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090) eisai.com ↗
The safety and efficacy findings are being featured in a poster discussion at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), a hybrid meeting in Chicago from June 3 to 7 ( NCT03386942 ; Abstract: #5513). |
| 2022-05-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders bms.com ↗
First dose expansion data for Eisai and Bristol Myers Squibb's co-developed antibody-drug conjugate MORAb-202, demonstrate anti-tumor activity in platinum-resistant ovarian cancer patients at two dose levels as well as benefits of exploration of body surface area dosing to optimize safety. |
| 2017-09-22 | Eisai Inc. | Results EISAI PRESENTS LATEST NON-CLINICAL DATA ON ITS FIRST ANTIBODY-DRUG CONJUGATE MORAB-202 AT 8th ANNUAL WORLD ADC eisai.com ↗
MORAb-202 demonstrated high selectivity for FRA-positive cancer cells, which are expressed in approximately 60% of triple-negative breast cancer patients, as well as strong antitumor activity. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Farletuzumab Ecteribulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03386942 ↗ |
| Known as | Farletuzumab ecteribul | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802212 ↗ |
| Known as | FZEC | “Farletuzumab ecteribulin (FZEC), an antibody-drug conjugate targeting folate receptor-alpha (FRα)” PMID 41993769 ↗ Jan 2026 |
| Known as | MORAb-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05577715 ↗ |
| Route | Intravenous | “farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks” NCT03386942 ↗ |